Research‐wise, the identification of additional relevant mutations in non‐responders to anti‐EGFR therapy might be possible only when focused on morphological regions, as exemplified by our finding of KRAS (p.Lys147Glu and p.Ala146Thr) mutations in mucinous and desmoplastic, but not serrated regions of a tumour, despite the latter having a larger proportion of neoplastic cells. This evidence concerns the gene KRAS and neoplasm.